Stock Events

Stock Events

Galecto Inc 

$24.79
35
-$1.11-4.29% Tuesday 19:55

Statistics

Day High
25.96
Day Low
24.77
52W High
34.14
52W Low
2.58
Volume
131,624
Avg. Volume
-
Mkt Cap
32.9M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
Next
-5.13
-3.12
-1.11
0.9
Expected EPS
-0.378908
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-42.88MNet Income

Analyst Ratings

43.4Average Price Target
The highest estimate is 46.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GLTO. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap11.84B
Madrigal Pharmaceuticals is involved in developing therapies for fibrosis, particularly NASH, a direct area of competition with Galecto.
Galapagos NV
GLPG
Mkt Cap1.88B
Galapagos NV specializes in drug discovery for fibrosis and other indications, overlapping with Galecto's research areas.
ProQR Therapeutics N.V
PRQR
Mkt Cap163.31M
ProQR Therapeutics works on treatments for fibrosis among other diseases, positioning it as a competitor in the fibrosis space.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences has a strong portfolio in treating fibrotic diseases, making it a major competitor to Galecto.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals has expanded its focus to include fibrosis, directly competing with Galecto's pipeline.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a broad range of treatments including for fibrosis, positioning it as a competitor across multiple areas including those targeted by Galecto.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie has research interests in fibrosis, making it a competitor in the therapeutic area Galecto is targeting.
Novartis
NVS
Mkt Cap279.67B
Novartis has a diversified portfolio that includes treatments for fibrosis, competing with Galecto in the fibrosis therapeutic area.

About

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Show more...
CEO
Ms. Lori C. Firmani
Employees
5
Country
United States
ISIN
US36322Q1076

Listings

XNAS
US
GLTO
BOATS
BOATS
GLTO.BOATS
XNAS
US
DMRA

0 Comments

Share your thoughts

FAQ

What is Galecto Inc stock price today?▼
The current price of GLTO is $24.79 USD — it has decreased by -4.29% in the past 24 hours. Watch Galecto Inc stock price performance more closely on the chart.
What is Galecto Inc stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Galecto Inc stocks are traded under the ticker GLTO.
Is Galecto Inc stock price growing?▼
GLTO stock has risen by +3.12% compared to the previous week, the month change is a -13.59% fall, over the last year Galecto Inc has showed a +731.88% increase.
What is Galecto Inc market cap?▼
Today Galecto Inc has the market capitalization of 32.9M
When is the next Galecto Inc earnings date?▼
Galecto Inc is going to release the next earnings report on August 05, 2026.
What is Galecto Inc revenue for the last year?▼
Galecto Inc revenue for the last year amounts to 0 USD.
What is Galecto Inc net income for the last year?▼
GLTO net income for the last year is -42.88M USD.
How many employees does Galecto Inc have?▼
As of May 06, 2026, the company has 5 employees.
In which sector is Galecto Inc located?▼
Galecto Inc operates in the Health & Wellness sector.
When did Galecto Inc complete a stock split?▼
The last stock split for Galecto Inc was on August 30, 2024 with a ratio of 1:25.
Where is Galecto Inc headquartered?▼
Galecto Inc is headquartered in Copenhagen, United States.